Giovanni Passalacqua

List of Publications by Year
in descending order

327	15,511	18482 62	23533 111
papers	citations	h-index	g-index

336	336	336	9023
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Legends of allergy and immunology: Giorgio Walter Canonicaâ€"Physician, scientist, and visionary leader. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 695-697.	5.7	0
2	Specific Therapy for T2 Asthma. Journal of Personalized Medicine, 2022, 12, 593.	2.5	7
3	Obituary in memory of Giovanni Pajno. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2578-2579.	5.7	0
4	ARIA digital anamorphosis: Digital transformation of health and care in airway diseases from research to practice. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 168-190.	5.7	46
5	ARIAâ€ŁAACI statement on asthma and COVIDâ€•19 (June 2, 2020). Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 689-697.	5.7	57
6	COVIDâ€•19 in severe asthmatic patients during ongoing treatment with biologicals targeting type 2 inflammation: Results from a multicenter Italian survey. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 871-874.	5.7	33
7	Asthma in a large COVID-19 cohort: Prevalence, features, and determinants of COVID-19 disease severity. Respiratory Medicine, 2021, 176, 106261.	2.9	44
8	Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 1041-1052.	5.7	38
9	Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life. World Allergy Organization Journal, 2021, 14, 100509.	3.5	14
10	Allergy and coronavirus disease (COVID-19) international survey: Real-life data from the allergy community during the pandemic. World Allergy Organization Journal, 2021, 14, 100515.	3.5	7
11	Differentiation of COVIDâ€•19 signs and symptoms from allergic rhinitis and common cold: An ARIAâ€ŁAACIâ€ŒA‹sup›2‹/sup›LEN consensus. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2354-2366.	5.7	31
12	ARIAâ€ŁAACI care pathways for allergen immunotherapy in respiratory allergy. Clinical and Translational Allergy, 2021, 11, e12014.	3.2	24
13	Real-life studies in allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2021, 21, 361-367.	2.3	7
14	Management of anaphylaxis due to COVIDâ€•19 vaccines in the elderly. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2952-2964.	5.7	16
15	Quick Olfactory Sniffinâ€™ Sticks Test (Q-Sticks) for the detection of smell disorders in COVID-19 patients. World Allergy Organization Journal, 2021, 14, 100497.	3.5	17
16	ARIA-ITALY multidisciplinary consensus on nasal polyposis and biological treatments. World Allergy Organization Journal, 2021, 14, 100592.	3.5	17
17	Severe asthma: One disease and multiple definitions. World Allergy Organization Journal, 2021, 14, 100606.	3.5	18
18	Next-generation Allergic Rhinitis and Its Impact on Asthma (ARIA) guidelines for allergic rhinitis based on Grading of Recommendations Assessment, Development and Evaluation (GRADE) and real-world evidence. Journal of Allergy and Clinical Immunology, 2020, 145, 70-80.e3.	2.9	272

#	Article	IF	Citations
19	Severe asthma, biologicals, and autoâ€injection: Yes, no, may be!. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 444-445.	5.7	6
20	30 years of sublingual immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1107-1120.	5.7	41
21	Evolving phenotypes to endotypes: is precision medicine achievable in asthma?. Expert Review of Respiratory Medicine, 2020, 14, 163-172.	2.5	7
22	Biologicals for severe asthma: what we can learn from real-life experiences?. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 64-70.	2.3	8
23	Long-term responsiveness to mepolizumab after failure of omalizumab and bronchial thermoplasty: Two triple-switch case reports. Respiratory Medicine Case Reports, 2020, 29, 100967.	0.4	6
24	The importance of being not significant: Blood eosinophils and clinical responses do not correlate in severe asthma patients treated with mepolizumab in real life. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1460-1463.	5.7	16
25	DUPILUMAB IMPROVES PATIENT-REPORTED BREATHING IN ORAL CORTICOSTEROID-DEPENDENT SEVERE ASTHMA. Chest, 2020, 158, A1752-A1754.	0.8	1
26	Oral CorticoSteroid sparing with biologics in severe asthma: A remark of the Severe Asthma Network in Italy (SANI). World Allergy Organization Journal, 2020, 13, 100464.	3.5	30
27	Clinical course and outcomes of patients with asthma hospitalized for severe acute respiratory syndrome coronavirus 2Âpneumonia. Annals of Allergy, Asthma and Immunology, 2020, 125, 707-709.	1.0	19
28	Clinical characteristics, management and in-hospital mortality of patients with coronavirus disease 2019 in Genoa, Italy. Clinical Microbiology and Infection, 2020, 26, 1537-1544.	6.0	84
29	Medical devices in allergy practice. World Allergy Organization Journal, 2020, 13, 100466.	3.5	7
30	COVID-19, asthma, and biological therapies: What we need to know. World Allergy Organization Journal, 2020, 13, 100126.	3.5	90
31	Do the current guidelines for asthma pharmacotherapy encourage over-treatment?. Expert Opinion on Pharmacotherapy, 2020, 21, 1283-1286.	1.8	4
32	A WAO â€" ARIA â€" GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020. World Allergy Organization Journal, 2020, 13, 100091.	3.5	76
33	Adherence to Allergen Subcutaneous Immunotherapy is Increased by a Shortened Build-Up Phase: A Retrospective Study. BioMed Research International, 2020, 2020, 1-4.	1.9	5
34	A prevalent exposure to male dog is a risk factor for exclusive allergic sensitization to Can f 5: An Italian multicenter study. Journal of Allergy and Clinical Immunology: in Practice, 2020, 8, 2399-2401.	3.8	5
35	IgE allergy diagnostics and other relevant tests in allergy, a World Allergy Organization position paper. World Allergy Organization Journal, 2020, 13, 100080.	3.5	245
36	Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. Respiratory Medicine, 2020, 171, 106080.	2.9	28

#	Article	IF	Citations
37	Biological agents for severe asthma: the evolution of the at-home self-injection approach. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 421-427.	2.3	15
38	Allergen immunotherapy for pediatric asthma: current evidence and knowledge gaps. Current Opinion in Allergy and Clinical Immunology, 2020, 20, 162-167.	2.3	7
39	Clinical efficacy of sublingual immunotherapy tablets for allergic rhinitis is unlikely to be derived from in vitro allergen-release data. Expert Review of Clinical Immunology, 2019, 15, 921-928.	3.0	7
40	Latin American chronic urticaria registry (CUR) contribution to the understanding and knowledge of the disease in the region. World Allergy Organization Journal, 2019, 12, 100042.	3.5	6
41	One year of mepolizumab. Efficacy and safety in real-life in Italy. Pulmonary Pharmacology and Therapeutics, 2019, 58, 101836.	2.6	57
42	Efficacy of mepolizumab in patients with previous omalizumab treatment failure: Realâ€life observation. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2539-2541.	5.7	36
43	2019 ARIA Care pathways for allergen immunotherapy. Allergy: European Journal of Allergy and Clinical Immunology, 2019, 74, 2087-2102.	5.7	140
44	The safety of oral immunotherapy for food allergy during maintenance phase: Effect of counselling on adverse reactions. World Allergy Organization Journal, 2019, 12, 100010.	3.5	13
45	Can f 5 as a suitable marker of dog allergy: Assess male dog exposure before banning it. Journal of Allergy and Clinical Immunology, 2019, 143, 1657-1658.	2.9	6
46	Efficacy and safety of honeybee and wasp tyrosine-adsorbed venom immunotherapy. World Allergy Organization Journal, 2019, 12, 100086.	3.5	0
47	Analysis of the drop-out rate in patients receiving mepolizumab for severe asthma in real life. Pulmonary Pharmacology and Therapeutics, 2019, 54, 87-89.	2.6	15
48	The Severe Asthma Network in Italy: Findings and Perspectives. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1462-1468.	3.8	112
49	Pharmacokinetics and pharmacodynamics of monoclonal antibodies for asthma treatment. Expert Opinion on Drug Metabolism and Toxicology, 2019, 15, 113-120.	3.3	14
50	Inhaled Corticosteroids Safety and Adverse Effects in Patients with Asthma. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 776-781.	3.8	118
51	Critical aspects in dog allergen immunotherapy (DAI). May Component Resolved Diagnosis (CRD) play a role in predicting the efficacy?. Human Vaccines and Immunotherapeutics, 2018, 14, 1438-1441.	3.3	6
52	Current insights in allergen immunotherapy. Annals of Allergy, Asthma and Immunology, 2018, 120, 152-154.	1.0	20
53	Evaluation of the safety of a protocol for switching venom immunotherapy products. Annals of Allergy, Asthma and Immunology, 2018, 120, 429-430.	1.0	8
54	Anaphylactic Reactions After Discontinuation of Hymenoptera Venom Immunotherapy: A Clonal Mast Cell Disorder Should Be Suspected. Journal of Allergy and Clinical Immunology: in Practice, 2018, 6, 1368-1372.	3.8	49

#	Article	IF	Citations
55	Asthma: personalized and precision medicine. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 51-58.	2.3	57
56	Allergen immunotherapy as add-on to biologic agents. Current Opinion in Allergy and Clinical Immunology, 2018, 18, 502-508.	2.3	14
57	The North-Western Italian experience with anti IL-5 therapy amd comparison with regulatory trials. World Allergy Organization Journal, 2018, 11, 34.	3.5	36
58	Anti-IL-5 and IL-5Ra: Efficacy and Safety of New Therapeutic Strategies in Severe Uncontrolled Asthma. BioMed Research International, 2018, 2018, 1-8.	1.9	42
59	The Relevance of Nasal Cytology in the Workup of House Dust Mite-Induced Allergic Rhinitis. Allergy, Asthma and Immunology Research, 2018, 10, 283.	2.9	2
60	Personalizing the approach to asthma treatment. Expert Review of Precision Medicine and Drug Development, 2018, 3, 299-304.	0.7	3
61	The control of allergic rhinitis in real life: a multicenter cross-sectional Italian study. Clinical and Molecular Allergy, 2018, 16, 4.	1.8	17
62	A critical appraisal on AIT in childhood asthma. Clinical and Molecular Allergy, 2018, 16, 6.	1.8	8
63	Nasal budesonide efficacy for nasal nitric oxide and nasal obstruction in rhinitis. Pediatric Allergy and Immunology, 2017, 28, 393-397.	2.6	6
64	Effect of adjuvanted and standard sublingual immunotherapy on respiratory function in pure rhinitis due to house dust mite over a 5-year period. World Allergy Organization Journal, 2017, 10, 7.	3.5	9
65	Allergic diseases in the elderly: biological characteristics and main immunological and non-immunological mechanisms. Clinical and Molecular Allergy, 2017, 15, 2.	1.8	27
66	Clinical practice recommendations for allergen-specific immunotherapy in children: the Italian consensus report. Italian Journal of Pediatrics, 2017, 43, 13.	2.6	71
67	Umeclidinium for the treatment of uncontrolled asthma. Expert Opinion on Investigational Drugs, 2017, 26, 761-766.	4.1	7
68	IL-13 and idiopathic pulmonary fibrosis: Possible links and new therapeutic strategies. Pulmonary Pharmacology and Therapeutics, 2017, 45, 95-100.	2.6	59
69	Allergen-Specific Immunotherapy for Respiratory Allergy in Children: Unmet Needs and Future Goals. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 946-950.	3.8	9
70	Allergic Rhinitis and its Impact on Asthma (ARIA) guidelinesâ€"2016 revision. Journal of Allergy and Clinical Immunology, 2017, 140, 950-958.	2.9	1,199
71	Targeting Interleukin-5 or Interleukin-5RÎ±: Safety Considerations. Drug Safety, 2017, 40, 559-570.	3.2	22
72	Perioperative midazolam hypersensitivity in a sevenâ€yearâ€old boy. Pediatric Allergy and Immunology, 2017, 28, 400-401.	2.6	10

#	Article	IF	Citations
73	The role of the pharmacy in the management of bronchial asthma. Annals of Allergy, Asthma and Immunology, 2017, 118, 161-165.	1.0	10
74	Hymenoptera venom allergy in outdoor workers: Occupational exposure, clinical features and effects of allergen immunotherapy. Human Vaccines and Immunotherapeutics, 2017, 13, 477-483.	3.3	8
75	Efficacy of Buffered Hypertonic Saline Nasal Irrigation for Nasal Symptoms in Children with Seasonal Allergic Rhinitis: A Randomized Controlled Trial. International Archives of Allergy and Immunology, 2017, 174, 97-103.	2.1	21
76	The current overuse and misuse of meta-analyses on sublingual immunotherapy: the case of grass pollen allergy. Current Opinion in Allergy and Clinical Immunology, 2017, 17, 12-16.	2.3	9
77	Anti-interleukin 5 therapies in severe asthma. Lancet Respiratory Medicine,the, 2017, 5, 537-538.	10.7	4
78	Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience. Therapeutic Advances in Respiratory Disease, 2017, 11, 40-45.	2.6	27
79	Local Side Effects of Sublingual and Oral Immunotherapy. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 13-21.	3.8	36
80	The relevance of house dust mites allergy in clinical practice: the epidemiological impact on allergen immunotherapy. Immunotherapy, 2017, 9, 1219-1224.	2.0	3
81	Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. Frontiers in Medicine, 2017, 4, 135.	2.6	65
82	How to fit allergen immunotherapy in the elderly. Clinical and Molecular Allergy, 2017, 15, 17.	1.8	6
83	Personalized Medicine in Allergy. Allergy, Asthma and Immunology Research, 2017, 9, 15.	2.9	40
84	Vitamin D levels and allergic diseases. An italian cross-sectional multicenter survey. European Annals of Allergy and Clinical Immunology, 2017, 49, 75-79.	1.0	8
85	Allergic and nonallergic rhinitis and skin sensitization to metals: is there a link?. European Annals of Allergy and Clinical Immunology, 2017, 49, 106-109.	1.0	4
86	The path to personalized medicine in asthma. Expert Review of Respiratory Medicine, 2016, 10, 957-965.	2.5	10
87	Update on immunotherapy for the treatment of asthma. Current Opinion in Pulmonary Medicine, 2016, 22, 18-24.	2.6	15
88	Development of a nomogram to estimate the quality of life in asthmatic children using the Childhood Asthma Control Test. Pediatric Allergy and Immunology, 2016, 27, 514-520.	2.6	15
89	Benefit of SLIT and SCIT for Allergic Rhinitis and Asthma. Current Allergy and Asthma Reports, 2016, 16, 88.	5.3	29
90	Therapeutic interventions in severe asthma. World Allergy Organization Journal, 2016, 9, 40.	3.5	38

#	Article	IF	Citations
91	Molecular diagnosis and precision medicine in allergy management. Clinical Chemistry and Laboratory Medicine, 2016, 54, 1705-1714.	2.3	20
92	The safety of monoclonal antibodies in asthma. Expert Opinion on Drug Safety, 2016, 15, 1087-1095.	2.4	8
93	Comparison of allergenic extracts from different origins: the value of the FDAâ€™s bioequivalent allergy unit (BAU). Expert Review of Clinical Immunology, 2016, 12, 733-739.	3.0	9
94	MACVIA clinical decision algorithm in adolescents and adults with allergic rhinitis. Journal of Allergy and Clinical Immunology, 2016, 138, 367-374.e2.	2.9	128
95	What lies beyond Asthma Control Test: Suggestions for clinical practice. Journal of Asthma, 2016, 53, 559-562.	1.7	5
96	A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma. International Archives of Allergy and Immunology, 2016, 170, 122-131.	2.1	164
97	MK-8237: a house dust mite vaccine for treating allergic rhinitis, asthma and atopic dermatitis. Expert Opinion on Biological Therapy, 2016, 16, 1435-1441.	3.1	1
98	Patient engagement and patient support programs in allergy immunotherapy: a call to action for improving long-term adherence. Allergy, Asthma and Clinical Immunology, 2016, 12, 34.	2.0	18
99	Risk and safety requirements for diagnostic and therapeutic procedures in allergology: World Allergy Organization Statement. World Allergy Organization Journal, 2016, 9, 33.	3.5	87
100	Local allergic rhinitis: entopy or spontaneous response?. World Allergy Organization Journal, 2016, 9, 39.	3.5	23
101	Potential of molecular based diagnostics and its impact on allergen immunotherapy. Asthma Research and Practice, 2016, 2, 9.	2.4	7
102	NASAL cytology: practical aspects and clinical relevance. Clinical and Experimental Allergy, 2016, 46, 785-792.	2.9	97
103	Management of the polyallergic patient with allergy immunotherapy: a practice-based approach. Allergy, Asthma and Clinical Immunology, 2016, 12, 2.	2.0	58
104	Phenotyping asthma in the elderly: allergic sensitization profile and upper airways comorbidity in patients older than 65 years. Annals of Allergy, Asthma and Immunology, 2016, 116, 206-211.	1.0	10
105	Molecular phenotyping and biomarker development: are we on our way towards targeted therapy for severe asthma?. Expert Review of Respiratory Medicine, 2016, 10, 29-38.	2.5	27
106	Orphan immunotherapies for allergic diseases. Annals of Allergy, Asthma and Immunology, 2016, 116, 194-198.	1.0	8
107	Allergen Immunotherapy. Immunology and Allergy Clinics of North America, 2016, 36, 1-12.	1.9	43
108	Efficacy and safety of sublingual immunotherapy in children. Expert Review of Clinical Immunology, 2016, 12, 49-56.	3.0	16

#	Article	IF	Citations
109	Sublingual grass and ragweed immunotherapy: Clinical considerationsâ€"a PRACTALL consensus report. Journal of Allergy and Clinical Immunology, 2016, 137, 369-376.	2.9	37
110	Drug Hypersensitivity Reactions in Patients with Clonal Mast Cells Disorders. Journal of Allergy and Clinical Immunology, 2015, 135, AB122.	2.9	1
111	The patient with rhinitis in the pharmacy. A cross-sectional study in real life. Asthma Research and Practice, 2015, 1, 4.	2.4	21
112	The perception of allergen-specific immunotherapy among pediatricians in the primary care setting. Clinical and Molecular Allergy, 2015, 13, 15.	1.8	14
113	AIT (allergen immunotherapy): a model for the â€œprecision medicineâ€• Clinical and Molecular Allergy, 2015, 13, 24.	1.8	26
114	Choosing the optimal dose in sublingual immunotherapy: Rationale for the 300Âindex of reactivity dose. Clinical and Translational Allergy, 2015, 5, 44.	3.2	20
115	Allergen immunotherapy on the way to product-based evaluationâ€"a WAO statement. World Allergy Organization Journal, 2015, 8, 29.	3.5	70
116	Allergen immunotherapy in asthma; what is new?. Asthma Research and Practice, 2015, 1, 6.	2.4	10
117	The care pathway for children with urticaria, angioedema, mastocytosis. World Allergy Organization Journal, 2015, 8, 5.	3.5	16
118	Clinical Characteristics Associated with Conjunctival Inflammation in Allergic Rhinoconjunctivitis. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 387-391.e1.	3.8	10
119	Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptaseÂlevels. Journal of Allergy and Clinical Immunology, 2015, 136, 135-139.	2.9	102
120	Oral Immunotherapy for Egg Allergy: A Double-Blind Placebo-Controlled Study, with Postdesensitization Follow-Up. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 532-539.	3.8	98
121	The evolution of allergen and non-specific immunotherapy: past achievements, current applications and future outlook. Expert Review of Clinical Immunology, 2015, 11, 141-154.	3.0	18
122	Sublingual immunotherapy: focus on tablets. Annals of Allergy, Asthma and Immunology, 2015, 115, 4-9.	1.0	14
123	Specific immunotherapy in asthma: a comprehensive review. Journal of Asthma, 2014, 51, 29-33.	1.7	21
124	Recommendations for appropriate sublingual immunotherapy clinical trials. World Allergy Organization Journal, 2014, 7, 21.	3.5	9
125	Crossâ€sectional comparison of the characteristics of respiratory allergy in immigrants and Italian children. Pediatric Allergy and Immunology, 2014, 25, 473-480.	2.6	13
126	Novelin silicotechnology in combination with microarrays: a state-of-the-art technology for allergy diagnosis and management?. Expert Review of Clinical Immunology, 2014, 10, 1559-1561.	3.0	7

#	Article	IF	Citations
127	Vitamin D, allergies and asthma: focus on pediatric patients. World Allergy Organization Journal, 2014, 7, 27.	3.5	19
128	COPD: maximization of bronchodilation. Multidisciplinary Respiratory Medicine, 2014, 9, 50.	1.5	17
129	The use of single versus multiple antigens in specific allergen immunotherapy for allergic rhinitis. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 20-24.	2.3	33
130	Poster 1001: ALLERGENIUSÂ®: an expert system for the interpretation of allergen microarrays. World Allergy Organization Journal, 2014, 7, P2.	3.5	0
131	Allergenius, an expert system for the interpretation of allergen microarray results. World Allergy Organization Journal, 2014, 7, 15.	3.5	32
132	Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organization Journal, 2014, 7, 6.	3.5	395
133	Ranking in importance of allergen extract characteristics for sublingual immunotherapy by Italian specialists. Allergy and Asthma Proceedings, 2014, 35, 43-46.	2.2	6
134	Adverse Effects Associated with Sublingual Immunotherapy. , 2014, , 461-468.		1
135	The perception of allergen-specific immunotherapy among Italian general practitioners. European Annals of Allergy and Clinical Immunology, 2014, 46, 83-6.	1.0	4
136	The perception of allergen-specific immunotherapy among chest physicians: an Italian survey. European Annals of Allergy and Clinical Immunology, 2014, 46, 132-6.	1.0	4
137	The additional values of microarray allergen assay in the management of polysensitized patients with respiratory allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1029-1033.	5.7	62
138	Efficacy of venom immunotherapy given every 3 or 4 months: a prospective comparison with the conventional regimen. Annals of Allergy, Asthma and Immunology, 2013, 110, 51-54.	1.0	31
139	Grading local side effects of sublingual immunotherapy forÂrespiratory allergy: Speaking the same language. Journal of Allergy and Clinical Immunology, 2013, 132, 93-98.	2.9	144
140	Will Sublingual Immunotherapy Offer Benefit for Asthma?. Current Allergy and Asthma Reports, 2013, 13, 571-579.	5.3	5
141	A WAO - ARIA - GAÂ²LEN consensus document on molecular-based allergy diagnostics. World Allergy Organization Journal, 2013, 6, 17.	3.5	352
142	Venom Immunotherapy in Patients with Clonal Mast Cell Disorders: Efficacy, Safety, and Practical Considerations. Journal of Allergy and Clinical Immunology: in Practice, 2013, 1, 474-478.	3.8	85
143	Allergy training and immunotherapy in Latin America: results of a regional overview. Annals of Allergy, Asthma and Immunology, 2013, 111, 415-419.e1.	1.0	20
144	Evaluation and Validation of A Bee Venom Sting Challenge Performed by A MICRO-Syringe. Journal of Allergy and Clinical Immunology, 2013, 131, AB25.	2.9	0

#	Article	IF	Citations
145	Adherence to pharmacological treatment and specific immunotherapy in allergic rhinitis. Clinical and Experimental Allergy, 2013, 43, 22-28.	2.9	60
146	NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on shortâ€term ILâ€2 activation. European Journal of Immunology, 2013, 43, 550-561.	2.9	41
147	Sublingual immunotherapy for allergic rhinitis and conjunctivitis. Immunotherapy, 2013, 5, 257-264.	2.0	24
148	Component-resolved diagnosis in pediatric allergic rhinoconjunctivitis and asthma. Current Opinion in Allergy and Clinical Immunology, 2013, 13, 446-451.	2.3	24
149	Efficacy of Sublingual Immunotherapy. JAMA - Journal of the American Medical Association, 2013, 310, 643.	7.4	5
150	100 Years of Immunotherapy: The Monaco Charter. International Archives of Allergy and Immunology, 2013, 160, 346-349.	2.1	12
151	Comparison between two maintenance feeding regimens after successful cow's milk oral desensitization. Pediatric Allergy and Immunology, 2013, 24, 376-381.	2.6	56
152	Causes of SLIT discontinuation and strategies to improve the adherence: a pragmatic approach. Allergy: European Journal of Allergy and Clinical Immunology, 2013, 68, 1193-1195.	5.7	44
153	When sneezing indicates the cell type. International Forum of Allergy and Rhinology, 2013, 3, 393-398.	2.8	9
154	Immunotherapy â€“ 2082. Long term prevention of asthma and rhinitis in children with atopic dermatitis four year after discontinuation of sublingual immunotherapy. World Allergy Organization Journal, 2013, 6, P163.	3.5	1
155	Changing the route of immunotherapy administration: An 18-year survey in pediatric patients with allergic rhinitis and asthma. Allergy and Asthma Proceedings, 2013, 34, 523-526.	2.2	14
156	Evidences of efficacy of allergen immunotherapy in atopic dermatitis. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 427-433.	2.3	33
157	Allergens and bacteria interaction in the induction of basophil activation. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 164-170.	2.3	6
158	Allergic and non-allergic rhinitis in swimmers: clinical and cytological aspects. British Journal of Sports Medicine, 2012, 46, 54-58.	6.7	40
159	Oral immunotherapy for cow's milk allergy. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 271-277.	2.3	22
160	Emerging drugs for perennial allergic rhinitis. Expert Opinion on Emerging Drugs, 2012, 17, 543-553.	2.4	0
161	Adherence to sublingual immunotherapy in preschool children. Pediatric Allergy and Immunology, 2012, 23, 688-689.	2.6	48
162	Evaluation and validation of a bee venom sting challenge performed by a micro-syringe. Annals of Allergy, Asthma and Immunology, 2012, 109, 438-441.	1.0	10

#	Article	IF	Citations
163	Latex immunotherapy: state of the art. Annals of Allergy, Asthma and Immunology, 2012, 109, 160-165.	1.0	33
164	The functional connection between oral allergy syndrome and united airways disease assessed by oral challenge. Annals of Allergy, Asthma and Immunology, 2012, 108, 30-33.	1.0	5
165	Immunotherapy in polysensitized patients: new chances for the allergists?. Annals of Allergy, Asthma and Immunology, 2012, 109, 392-394.	1.0	11
166	EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy. Clinical and Translational Allergy, 2012, 2, 20.	3.2	97
167	Hypersensitivity to proton pump inhibitors: Diagnostic accuracy of skin tests compared to oral provocation test. Journal of Allergy and Clinical Immunology, 2012, 130, 547-549.	2.9	50
168	Clinical and cytologic characteristics of allergic rhinitis in elderly patients. Annals of Allergy, Asthma and Immunology, 2012, 108, 141-144.	1.0	24
169	Effects of Different Up-Dosing Regimens for Hymenoptera Venom Immunotherapy on Serum CTLA-4 and IL-10. PLoS ONE, 2012, 7, e37980.	2.5	11
170	The IgE repertoire in children and adolescents resolved at component level: A crossâ€sectional study. Pediatric Allergy and Immunology, 2012, 23, 433-440.	2.6	59
171	The role of basophil activation test in special populations with mastocytosis and reactions to hymenoptera sting. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 962-965.	5.7	37
172	Management of chronic rhinosinusitis. Pediatric Allergy and Immunology, 2012, 23, 32-44.	2.6	18
173	Birch-Apple Syndrome Treated with Birch Pollen Immunotherapy. International Archives of Allergy and Immunology, 2011, 156, 416-422.	2.1	79
174	The possible influence of the environment on respiratory allergy: a survey on immigrants to Italy. Annals of Allergy, Asthma and Immunology, 2011, 106, 407-411.	1.0	20
175	Allergy and the bone: unexpected relationships. Annals of Allergy, Asthma and Immunology, 2011, 107, 202-206.	1.0	8
176	Sublingual Immunotherapy for Allergic Respiratory Diseases: Efficacy and Safety. Immunology and Allergy Clinics of North America, 2011, 31, 265-277.	1.9	11
177	Sublingual Immunotherapy: Other Indications. Immunology and Allergy Clinics of North America, 2011, 31, 279-287.	1.9	12
178	The Consolidated Standards of Reporting Trials (CONSORT) Statement applied to allergen-specific immunotherapy with inhalant allergens: ÂGlobal Allergy and Asthma European Network (GA2LEN) article. Journal of Allergy and Clinical Immunology, 2011, 127, 49-56.e11.	2.9	42
179	Disease-modifying effect and economic implications ofÂsublingual immunotherapy. Journal of Allergy and Clinical Immunology, 2011, 127, 44-45.	2.9	26
180	Specific immunotherapy: beyond the clinical scores. Annals of Allergy, Asthma and Immunology, 2011, 107, 401-406.	1.0	38

#	Article	IF	Citations
181	Bone mineral density, bone turnover markers and fractures in patients with indolent systemic mastocytosis. Bone, 2011, 49, 880-885.	2.9	95
182	Long-term survival in elderly patients with a do-not-intubate order treated with noninvasive mechanical ventilation. International Journal of COPD, 2011, 6, 253.	2.3	13
183	Sublingual immunotherapy for allergic rhinitis: an update. Current Opinion in Otolaryngology and Head and Neck Surgery, 2011, 19, 43-47.	1.8	7
184	An evidence-based appraisal of the surrogate markers of efficacy of allergen immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 375-380.	2.3	17
185	Specific immunotherapy, one century later. Current Opinion in Allergy and Clinical Immunology, 2011, 11, 551-553.	2.3	2
186	New approaches to the design of sublingual immunotherapy clinical trials. Clinical Investigation, 2011, 1, 805-814.	0.0	0
187	The classification of allergic rhinitis and its cytological correlate. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 1624-1625.	5.7	31
188	Association of Blattella germanica sensitization with atopic diseases in pediatric allergic patients. Pediatric Allergy and Immunology, 2011, 22, 521-527.	2.6	6
189	Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: A randomized controlled study. Pediatric Allergy and Immunology, 2011, 22, 803-807.	2.6	47
190	Specific immunotherapy in asthma: efficacy and safety. Clinical and Experimental Allergy, 2011, 41, 1247-1255.	2.9	41
191	Diagnostic tools in Rhinology EAACI position paper. Clinical and Translational Allergy, 2011, 1, 2.	3.2	156
192	The ImmunoCAP ISAC molecular allergology approach in adult multi-sensitized Italian patients with respiratory symptoms. Clinical Biochemistry, 2011, 44, 1005-1011.	1.9	91
193	Impact of Bariatric Surgery on Pulmonary Function and Nitric Oxide in Asthmatic and Non-Asthmatic Obese Patients. Journal of Asthma, 2011, 48, 553-557.	1.7	21
194	Sublingual Immunotherapy: Clinical Indications in the WAO-SLIT Position Paper. World Allergy Organization Journal, 2010, 3, 216-219.	3.5	18
195	Adherence issues related to sublingual immunotherapy as perceived by allergists. Patient Preference and Adherence, 2010, 4, 141.	1.8	28
196	The link between allergic rhinitis and asthma: the united airways disease. Expert Review of Clinical Immunology, 2010, 6, 413-423.	3.0	145
197	Investigational drugs for allergic rhinitis. Expert Opinion on Investigational Drugs, 2010, 19, 93-103.	4.1	6
198	Bridging allergologic and botanical knowledge in seasonal allergy: a role for phenology. Annals of Allergy, Asthma and Immunology, 2010, 105, 223-227.	1.0	46

#	Article	IF	Citations
199	Possible role of climate changes in variations in pollen seasons and allergic sensitizations during 27 years. Annals of Allergy, Asthma and Immunology, 2010, 104, 215-222.	1.0	141
200	Sublingual immunotherapy for Alternaria-induced allergic rhinitis: a randomized placebo-controlled trial. Annals of Allergy, Asthma and Immunology, 2010, 105, 382-386.	1.0	38
201	Nasal inflammation in vernal keratoconjunctivitis. Journal of Allergy and Clinical Immunology, 2010, 125, 496-498.	2.9	6
202	Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System. Journal of Allergy and Clinical Immunology, 2010, 125, 569-574.e7.	2.9	406
203	Considerations about the evaluation of the SLIT meta-analyses. Journal of Allergy and Clinical Immunology, 2010, 125, 509.	2.9	6
204	How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers' viewpoint. Journal of Allergy and Clinical Immunology, 2010, 126, 668-669.	2.9	95
205	Long-lasting effects of sublingual immunotherapy according to its duration: AÂ15-year prospective study. Journal of Allergy and Clinical Immunology, 2010, 126, 969-975.	2.9	312
206	Oral immunotherapy for cow's milk allergy with a weekly up-dosing regimen: a randomized single-blind controlled study. Annals of Allergy, Asthma and Immunology, 2010, 105, 376-381.	1.0	180
207	Emerging sublingual immunotherapy drugs. Expert Opinion on Pharmacotherapy, 2010, 11, 2963-2972.	1.8	2
208	Functionally relevant decreases in activatory receptor expression on NK cells are associated with pulmonary tuberculosis in vivo and persist after successful treatment. International Immunology, 2009, 21, 779-791.	4.0	61
209	Safety and efficacy of immunotherapy with Polistes dominulus venom: results from a large Italian database. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1229-1230.	5.7	9
210	Systemic reactions to peach are associated with high levels of specific IgE to Pru p 3. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1795-1796.	5.7	25
211	Adherence to sublingual immunotherapy: the allergists' viewpoint. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1796-1797.	5.7	16
212	Subâ€lingual Immunotherapy: World Allergy Organization Position Paper 2009. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 1-59.	5.7	316
213	Clinical effects of a Longâ€term Educational Program for Children with Asthma â€“ Aironet^{Â®}. A 1â€yr randomized controlled trial. Pediatric Allergy and Immunology, 2009, 20, 654-659.	2.6	16
214	Serum cytotoxic T lymphocyteâ€“associated antigen 4 in Hymenoptera venom allergy and its modulation by specific immunotherapy. Journal of Allergy and Clinical Immunology, 2009, 123, 258-260.	2.9	8
215	Clonal mast cell disorders in patients with systemic reactions to Hymenoptera stings and increased serum tryptase levels. Journal of Allergy and Clinical Immunology, 2009, 123, 680-686.	2.9	360
216	Recommendations for appropriate sublingual immunotherapy clinical trials. Journal of Allergy and Clinical Immunology, 2009, 124, 665-670.	2.9	77

#	Article	IF	Citations
217	Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Annals of Allergy, Asthma and Immunology, 2009, 102, 22-28.	1.0	82
218	Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due tograss pollen. Annals of Allergy, Asthma and Immunology, 2009, 102, 69-75.	1.0	44
219	Blowing a nose black and blue. Lancet, The, 2009, 373, 780.	13.7	7
220	Sublingual immunotherapy: where do we stand? Present and future. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 1-3.	2.3	11
221	A new protocol for specific oral tolerance induction in children with IgE-mediated cow's milk allergy. Allergy and Asthma Proceedings, 2009, 30, 443-448.	2.2	65
222	When Allergic Rhinitis is not Only Allergic. American Journal of Rhinology and Allergy, 2009, 23, 312-315.	2.0	27
223	Sub-Lingual Immunotherapy. World Allergy Organization Journal, 2009, 2, 233-281.	3.5	100
224	Advances in Allergen-Specific Immunotherapy. Current Drug Targets, 2009, 10, 1255-1262.	2.1	10
225	Large local reactions from stinging insects: from epidemiology to management. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 334-337.	2.3	53
226	Evidence of adherence to allergen-specific immunotherapy. Current Opinion in Allergy and Clinical Immunology, 2009, 9, 544-548.	2.3	78
227	New Insights into Allergen-Specific Immunotherapy in Rhinitis and Asthma. , 2009, , 195-215.		0
228	ALLERGY Net: The safety of sublingual immunotherapy with one or more allergens in adults. Allergy: European Journal of Allergy and Clinical Immunology, 2008, 63, 375-376.	5.7	37
229	Metaanalysis of the Efficacy of Sublingual Immunotherapy in the Treatment of Allergic Asthma in Pediatric Patients, 3 to 18 Years of Age. Chest, 2008, 133, 599-609.	0.8	263
230	Allergen specific immunotherapy is safe and effective in patients with systemic mastocytosis and Hymenoptera allergy. Journal of Allergy and Clinical Immunology, 2008, 121, 256-257.	2.9	67
231	Sublingual immunotherapy for large local reactions caused by honeybee sting: A double-blind, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 2008, 122, 44-48.	2.9	79
232	Preventive effects of sublingual immunotherapy in childhood: an open randomized controlled study. Annals of Allergy, Asthma and Immunology, 2008, 101, 206-211.	1.0	213
233	Factors that influence exhaled nitric oxide in Italian schoolchildren. Annals of Allergy, Asthma and Immunology, 2008, 101, 407-412.	1.0	24
234	Levocetirizine in persistent allergic rhinitis: continuous or on-demand use? A pilot study. Current Medical Research and Opinion, 2008, 24, 2829-2839.	1.9	33

#	Article	IF	Citations
235	The Clinical Characteristics of Respiratory Allergy in Immigrants in Northern Italy. International Archives of Allergy and Immunology, 2008, 147, 231-234.	2.1	18
236	Is Sublingual Immunotherapy the Final Answer? Implications for the Allergist. World Allergy Organization Journal, 2008, 1, 70-72.	3.5	0
237	Administration of sublingual vaccines. Clinical Allergy and Immunology, 2008, 21, 333-41.	0.7	0
238	Adverse effects associated with sublingual immunotherapy. Clinical Allergy and Immunology, 2008, 21, 469-75.	0.7	0
239	Preventive effects of sublingual immunotherapy. Drugs of Today, 2008, 44 Suppl B, 83-6.	1.1	0
240	Tubercular tracheoesophageal fistulas in AIDS patients: primary repair and no surgery required?. Aids, 2007, 21, 2561-2564.	2.2	8
241	The Safety of Allergen Specific Sublingual Immunotherapy. Current Drug Safety, 2007, 2, 117-123.	0.6	31
242	Allergic Rhinitis in Women. Women's Health, 2007, 3, 603-611.	1.5	0
243	Targeted therapy for allergic asthma: predicting and evaluating response to omalizumab. Expert Review of Clinical Immunology, 2007, 3, 463-467.	3.0	1
244	Immunotherapy: clinical trials â€“ optimal trial and clinical outcomes. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 561-566.	2.3	25
245	New perspectives in the treatment of allergic rhinitis and asthma in children. Current Opinion in Allergy and Clinical Immunology, 2007, 7, 201-206.	2.3	12
246	Role of contact sensitization in chronic urticaria. Journal of the American Academy of Dermatology, 2007, 56, 88-90.	1.2	49
247	Effects of sublingual immunotherapy for multiple or single allergens in polysensitized patients. Annals of Allergy, Asthma and Immunology, 2007, 98, 274-280.	1.0	107
248	Intimate behavior and allergy: a narrative review. Annals of Allergy, Asthma and Immunology, 2007, 99, 394-400.	1.0	36
249	Allergic Rhinitis and its Impact on Asthma update: Allergen immunotherapy. Journal of Allergy and Clinical Immunology, 2007, 119, 881-891.	2.9	251
250	Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: A randomized, double-blind, placebo-controlled study. Journal of Allergy and Clinical Immunology, 2007, 120, 164-170.	2.9	210
251	Treatment with American Polistes venom was ineffective in an Italian patient allergic to European Polistes. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 966-967.	5.7	11
252	Angioedema after administration of methylprednisolone to treat drug allergy. Allergy: European Journal of Allergy and Clinical Immunology, 2007, 62, 1346-1348.	5.7	15

#	Article	IF	Citations
253	Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children (EASY Project: Evaluation of A novel SLIT formulation during a Year). Pediatric Allergy and Immunology, 2007, 18, 58-62.	2.6	57
254	Ass's milk in children with atopic dermatitis and cow's milk allergy: Crossover comparison with goat's milk. Pediatric Allergy and Immunology, 2007, 18, 594-598.	2.6	73
255	Reply to the letter by Dr de Bot. Pediatric Allergy and Immunology, 2007, 18, 628-628.	2.6	0
256	Safety Profile of Sublingual Immunotherapy. Treatments in Respiratory Medicine, 2006, 5, 225-234.	1.4	7
257	Randomized open comparison of the safety of SLIT in a no-updosing and traditional updosing schedule in patients with Parietaria allergy. Allergologia Et Immunopathologia, 2006, 34, 82-83.	1.7	16
258	Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Annals of Allergy, Asthma and Immunology, 2006, 97, 141-148.	1.0	288
259	Economic evaluation of sublingual immunotherapy vs symptomatic treatment in adults with pollen-induced respiratory allergy: the Sublingual Immunotherapy Pollen Allergy Italy (SPAI) study. Annals of Allergy, Asthma and Immunology, 2006, 97, 615-621.	1.0	62
260	Seasonal sensorineural hearing loss associated with allergic rhinitis: A case report. Journal of Allergy and Clinical Immunology, 2006, 117, 468-469.	2.9	4
261	ARIA update: Iâ€"Systematic review of complementary and alternative medicine for rhinitis and asthma. Journal of Allergy and Clinical Immunology, 2006, 117, 1054-1062.	2.9	141
262	Quantitative assessment of the compliance with a once-daily sublingual immunotherapy regimen in real life (EASY Project: Evaluation of A novel SLIT formulation during a Year). Journal of Allergy and Clinical Immunology, 2006, 117, 946-948.	2.9	51
263	Sublingual immunotherapy: update 2006. Current Opinion in Allergy and Clinical Immunology, 2006, 6, 449-454.	2.3	26
264	Local Nasal Specific Immunotherapy for Allergic Rhinitis. Allergy, Asthma and Clinical Immunology, 2006, 2, 117.	2.0	20
265	Specific immunotherapy among Italian specialists. Allergy: European Journal of Allergy and Clinical Immunology, 2006, 61, 898-899.	5.7	6
266	New insights in sublingual immunotherapy. Current Allergy and Asthma Reports, 2006, 6, 407-412.	5.3	7
267	Non-Injection Routes for Allergen Immunotherapy: Focus on Sublingual Immunotherapy. Inflammation and Allergy: Drug Targets, 2006, 5, 43-51.	1.8	11
268	Sensitization to Rabbit Allergens in Italy â€" A Multicentre Study in Atopic Subjects without Occupational Exposure. International Archives of Allergy and Immunology, 2006, 141, 295-299.	2.1	13
269	Novel therapeutic interventions for allergic rhinitis. Expert Opinion on Investigational Drugs, 2006, 15, 1615-1625.	4.1	7
270	Safety and pharmacoeconomics of a cluster administration of mite immunotherapy compared to the traditional one. European Annals of Allergy and Clinical Immunology, 2006, 38, 31-4.	1.0	17

#	Article	IF	Citations
271	Are Physicians Aware of the Side Effects of Angiotensin-Converting Enzyme Inhibitors?. Chest, 2005, 128, 976-979.	0.8	27
272	Sublingual immunotherapy in pediatric patients: beyond clinical efficacy. Current Opinion in Allergy and Clinical Immunology, 2005, 5, 173-177.	2.3	16
273	Latex-jujube cross-reactivity: case report and immunological study. Allergy: European Journal of Allergy and Clinical Immunology, 2005, 60, 971-972.	5.7	2
274	Pharmacokinetics of radiolabelled Par j 1 administered intranasally to allergic and healthy subjects. Clinical and Experimental Allergy, 2005, 35, 880-883.	2.9	19
275	Complementary/alternative medicines in allergic disease. Expert Review of Clinical Immunology, 2005, 1, 113-121.	3.0	1
276	Pharmacokinetics of Der p 2 Allergen and Derived Monomeric Allergoid in Allergic Volunteers. International Archives of Allergy and Immunology, 2005, 138, 197-202.	2.1	56
277	Nasal Eosinophils Display the Best Correlation with Symptoms, Pulmonary Function and Inflammation in Allergic Rhinitis. International Archives of Allergy and Immunology, 2005, 136, 266-272.	2.1	81
278	TIPS with Expanded Polytetrafluoroethyleneâ€“Covered Stent: Results of an Italian Multicenter Study. American Journal of Roentgenology, 2005, 185, 472-480.	2.2	97
279	Emerging anti-inflammatory agents for allergic rhinitis. Expert Opinion on Emerging Drugs, 2005, 10, 689-705.	2.4	6
280	A Review of the Evidence from Comparative Studies of Levocetirizine and Desloratadine for the Symptoms of Allergic Rhinitis. Clinical Therapeutics, 2005, 27, 979-992.	2.5	30
281	Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: A 3-year randomized controlled study. Journal of Allergy and Clinical Immunology, 2005, 115, 1184-1188.	2.9	81
282	An Update on Sublingual Immunotherapy. Allergy and Clinical Immunology International, 2005, 17, 181-185.	0.3	1
283	Comparison of the Effects in the Nose and Skin of a Single Dose of Desloratadine and Levocetirizine over 24 Hours. International Archives of Allergy and Immunology, 2004, 135, 143-147.	2.1	29
284	Future and experimental therapeutic strategies for allergic rhinitis and asthma. Therapy: Open Access in Clinical Medicine, 2004, 1, 277-288.	0.2	0
285	Euro coins and contact dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2004, 59, 669-670.	5.7	5
286	Efficacy and safety of sublingual immunotherapy. Annals of Allergy, Asthma and Immunology, 2004, 93, 3-12.	1.0	87
287	Quantitative assessment of the adherence to sublingual immunotherapy. Journal of Allergy and Clinical Immunology, 2004, 113, 1219-1220.	2.9	77
288	Sublingual immunotherapy: what lessons can we draw from recent studies?. Revue Francaise D'allergologie Et D'immunologie Clinique, 2004, 44, 584-589.	0.1	1

#	Article	IF	Citations
289	Sublingual immunotherapy: an update. Current Opinion in Allergy and Clinical Immunology, 2004, 4, 31-36.	2.3	28
290	An update on the asthma-rhinitis link. Current Opinion in Allergy and Clinical Immunology, 2004, 4, 177-183.	2.3	48
291	Noninjection Immunotherapy. Allergy and Clinical Immunology International, 2004, 16, 96-102.	0.3	2
292	Future and experimental therapeutic strategies for allergic rhinitis and asthma. Therapy: Open Access in Clinical Medicine, 2004, 1, 277-288.	0.2	0
293	The asthma-rhinitis association: Between the clinical hypothesis and the scientific theory. Current Allergy and Asthma Reports, 2003, 3, 191-193.	5.3	3
294	Non-specific bronchial hyper-responsiveness in children with allergic rhinitis: Relationship with the atopic status. Pediatric Allergy and Immunology, 2003, 14, 458-463.	2.6	23
295	Clinical and therapeutic aspects of allergic asthma in adolescents. Pediatric Allergy and Immunology, 2003, 14, 453-457.	2.6	12
296	Anaphylaxis caused by skin prick testing with aeroallergens: Case report and evaluation of the risk in Italian allergy services. Journal of Allergy and Clinical Immunology, 2003, 111, 1410-1412.	2.9	24
297	Effects of fexofenadine and other antihistamines on components of the allergic response. Journal of Allergy and Clinical Immunology, 2003, 112, S78-S82.	2.9	46
298	Noninjection routes for immunotherapy. Journal of Allergy and Clinical Immunology, 2003, 111, 437-448.	2.9	266
299	Does allergic rhinosinusitis exist?. Revue Francaise D'allergologie Et D'immunologie Clinique, 2003, 43, 236-239.	0.1	0
300	Treatment of acquired cold urticaria with cetirizine and zafirlukast in combination. Journal of the American Academy of Dermatology, 2003, 49, 714-716.	1.2	44
301	Focus on Cat Allergen (Fel d 1): Immunological and Aerodynamic Characteristics, Modality of Airway Sensitization and Avoidance Strategies. International Archives of Allergy and Immunology, 2003, 132, 1-12.	2.1	48
302	Oral and sublingual immunotherapy in paediatric patients. Current Opinion in Allergy and Clinical Immunology, 2003, 3, 139-145.	2.3	18
303	Safety of Allergen-Specific Sublingual Immunotherapy and Nasal Immunotherapy. , 2003, 82, 109-118.		6
304	Allergen Biodistribution in Humans. , 2003, 82, 33-43.		6
305	Asthma â€“ Rhinitis Comorbidity. Allergy and Clinical Immunology International, 2003, 15, 105-109.	0.3	2
306	Anaphylaxis due to patent blue dye during lymphography, with negative skin prick test. Journal of Investigational Allergology and Clinical Immunology, 2003, 13, 71-2.	1.3	16

#	Article	IF	Citations
307	Nimesulide and meloxicam are a safe alternative drugs for patients intolerant to nonsteroidal anti-inflammatory drugs. European Annals of Allergy and Clinical Immunology, 2003, 35, 393-6.	1.0	10
308	Sublingual immunotherapy. Revista Alergia Mexico, 2003, 50, 220-5.	0.1	1
309	Single-Dose Oral Tolerance Test with Alternative Compounds for the Management of Adverse Reactions to Drugs. International Archives of Allergy and Immunology, 2002, 129, 242-247.	2.1	12
310	Harmful effect of immunotherapy in children with combined snail and mite allergy. Journal of Allergy and Clinical Immunology, 2002, 109, 627-629.	2.9	71
311	Underdiagnosis and Undertreatment of Asthma: A 9-Year Study of Italian Conscripts. International Archives of Allergy and Immunology, 2001, 125, 211-215.	2.1	25
312	Antihistamines in the Treatment of Bronchial Asthma. Present Knowledge and Future Perspectives. Pulmonary Pharmacology and Therapeutics, 2001, 14, 267-276.	2.6	14
313	Intranasal mometasone furoate reduces late-phase inflammation after allergen challenge. Annals of Allergy, Asthma and Immunology, 2001, 86, 433-438.	1.0	32
314	Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Annals of Allergy, Asthma and Immunology, 2001, 87, 222-226.	1.0	51
315	Allergen-Specific Sublingual Immunotherapy for Respiratory Allergy. BioDrugs, 2001, 15, 509-519.	4.6	17
316	The noseÂ–lung interaction in allergic rhinitis and asthma: united airways disease. Current Opinion in Allergy and Clinical Immunology, 2001, 1, 7-13.	2.3	138
317	Nonsteroidal Antiallergic Treatments in Allergic Rhinitis. American Journal of Rhinology & Allergy, 2000, 14, 319-324.	2.2	5
318	United airways disease: therapeutic aspects. Thorax, 2000, 55, 26S-27.	5.6	106
319	Clinical and immunologic effects of a rush sublingual immunotherapy to Parietaria species: A double-blind, placebo-controlled trialâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 1999, 104, 964-968.	2.9	155
320	Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet, The, 1998, 351, 629-632.	13.7	252
321	Allergen-Specific Nasal Challenge: Response Kinetics of Clinical and Inflammatory Events to Rechallenge. International Archives of Allergy and Immunology, 1998, 115, 157-161.	2.1	27
322	Absorption and distribution kinetics of the major Parietaria judaica allergen (Par j 1) administered by noninjectable routes in healthy human beingsâ˜†â˜†â˜†.... Journal of Allergy and Clinical Immunology, 1997, 100, 122-129.	2.9	134
323	Continuous Versus On Demand Treatment with Cetirizine for Allergic Rhinitis. Annals of Allergy, Asthma and Immunology, 1997, 79, 507-511.	1.0	62
324	Molecular events in allergic inflammation: experimental models and possible modulation. Allergy: European Journal of Allergy and Clinical Immunology, 1997, 52, 25-30.	5.7	15

#	Article	IF	Citations
325	Nimesulide in the Treatment of Patients Intolerant of Aspirin and other NSAIDs. Drug Safety, 1996, 14, 94-103.	3.2	31
326	Cetirizine reduces inflammatory cell recruitment and ICAM-1 (or CD54) expression on conjunctival epithelium in both early- and late-phase reactions after allergen-specific challenge. Journal of Allergy and Clinical Immunology, 1995, 95, 612-621.	2.9	136
327	Antihistamines in atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 1989, 44, 114-116.	5.7	1